The first MedTech Funding Mandate policy published in England


Feb 2021

On January 26, 2021, NHS Accelerated Access Collaborative published the MedTech Funding Mandate policy for 2021/22, which will come into force in April 2021. According to the NHS Long Term Plan, introducing a MedTech Funding Mandate will support getting innovative medical devices, diagnostics, and digital products to patients faster.

Only technologies previously supported by the Innovation Technology Payment (ITP) will be included for the first year. To date, NHS England and NHS Improvement have funded the cost of procuring products on the ITP programs by directly reimbursing the supplier. The MedTech Funding Mandate does not directly fund the technologies included in the policy, and they will be reimbursed locally by Clinical Commissioning Groups (CCG).

MedTech Funding Mandate technologies are listed in the National Tariff Payment System (NTPS) Annex A (Innovative products list 13c). Technologies in the MedTech Funding Mandate can be procured through the relevant NHS Supply Chain framework from April 01, 2021.

MedTech Funding Mandate supports devices, diagnostics, or digital products that:

  • Are effective (demonstrated through positive NICE guidance);
  • Deliver material savings to the NHS (the benefits of the innovation are over £1 million over five years for the population of England);
  • Are cost-saving in-year (NICE modeling demonstrates a net saving in the first 12 months of implementing the technology);
  • Are affordable to the NHS (the budget impact should not exceed £20 million in any of the first three years).

The technologies that the policy will support in 2021/22 are:

  • Placental growth factor (PIGF) based testing – a blood test to rule out pre-eclampsia in pregnant women;
  • SecurAcath – for securing percutaneous catheters;
  • HeartFlow FFRCT– to create a 3D model of a patient's coronary arteries and assess the extent and location of blockages, estimating fractional flow reserve from coronary CT angiography;
  • gammaCore - a non-invasive vagus nerve stimulation therapy for treating cluster migraine.

Together with technology suppliers, NHS will work with patients and the Academic Health Science Networks (AHSNs) to support NHS organizations in implementing these innovations, understanding local and regional issues, and sharing learning from NHS organizations who have already implemented the innovations.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news


Jan 2023

The updated German Uniform Evaluation Standard (EBM) catalog came into force on January 1, 2023. The EBM catalog (Einheitlicher Bewertungsmaßstab) regulates the reimbursement of services in the public outpatient sector in Germany and is updated once a quarter (four times a year). Among other changes, a new code for "zanadio" health app for follow-up and evaluation was introduced in the catalog.

Read more


Jan 2023

On December 31, 2022, the Decree defining the reimbursement of medical telemonitoring activities via the new framework was published in the Official Journal of the French Republic. The Decree determines the methods of evaluation of digital solutions, registration for reimbursement, modification of the registration conditions, removal and invoicing of medical telemonitoring activities, as well as the conditions for setting the reimbursement packages.

Read more


Jan 2023

In December 2022, NHS England launched a consultation on the preliminary 2023/25 NHS Payment Scheme, which is set for two years and will replace the National Tariff Payment System from April 2023. Two new cardiovascular categories (antibacterial envelope, mitral valve repair and replacement devices) are proposed for inclusion in the 2023/24 High Cost Device List (will be updated and reissued for 2024/25). The deadline for comments submission is January 27, 2023.

Read more


Jan 2023

On December 26, 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by sickness funds.

Read more


Jan 2023

In December 2022, the National Institute for Health and Care Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned laser therapy in diabetic macular oedema, EarlyCDT Lung blood test, video-assisted thoracoscopic or open lobectomy, urethral slings for stress urinary incontinence, placental growth factor (PlGF) and sFlt-1 tests, and photobiomodulation in the management of oral mucositis. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more